AU2022215118A1 - Compounds for use in the treatment of attention deficit hyperactivity disorder - Google Patents

Compounds for use in the treatment of attention deficit hyperactivity disorder Download PDF

Info

Publication number
AU2022215118A1
AU2022215118A1 AU2022215118A AU2022215118A AU2022215118A1 AU 2022215118 A1 AU2022215118 A1 AU 2022215118A1 AU 2022215118 A AU2022215118 A AU 2022215118A AU 2022215118 A AU2022215118 A AU 2022215118A AU 2022215118 A1 AU2022215118 A1 AU 2022215118A1
Authority
AU
Australia
Prior art keywords
compound
adhd
dose
formula
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022215118A
Other languages
English (en)
Other versions
AU2022215118A9 (en
Inventor
Karl Ægir KARLSSON
Haraldur ÞORSTEINSSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3Z ehf
Original Assignee
3Z ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2101292.7A external-priority patent/GB202101292D0/en
Priority claimed from GBGB2101291.9A external-priority patent/GB202101291D0/en
Priority claimed from GBGB2101296.8A external-priority patent/GB202101296D0/en
Application filed by 3Z ehf filed Critical 3Z ehf
Publication of AU2022215118A1 publication Critical patent/AU2022215118A1/en
Publication of AU2022215118A9 publication Critical patent/AU2022215118A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2022215118A 2021-01-29 2022-01-28 Compounds for use in the treatment of attention deficit hyperactivity disorder Pending AU2022215118A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2101292.7A GB202101292D0 (en) 2021-01-29 2021-01-29 Novel treatments
GBGB2101291.9A GB202101291D0 (en) 2021-01-29 2021-01-29 Novel treatments
GB2101296.8 2021-01-29
GB2101291.9 2021-01-29
GB2101292.7 2021-01-29
GBGB2101296.8A GB202101296D0 (en) 2021-01-29 2021-01-29 Novel treatments
PCT/EP2022/052142 WO2022162199A2 (en) 2021-01-29 2022-01-28 Novel treatments

Publications (2)

Publication Number Publication Date
AU2022215118A1 true AU2022215118A1 (en) 2023-08-17
AU2022215118A9 AU2022215118A9 (en) 2024-05-16

Family

ID=80682355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022215118A Pending AU2022215118A1 (en) 2021-01-29 2022-01-28 Compounds for use in the treatment of attention deficit hyperactivity disorder

Country Status (12)

Country Link
US (1) US20240130995A1 (https=)
EP (1) EP4284356B1 (https=)
JP (1) JP2024508372A (https=)
AU (1) AU2022215118A1 (https=)
CA (1) CA3206935A1 (https=)
ES (1) ES3038949T3 (https=)
HR (1) HRP20250747T1 (https=)
HU (1) HUE071725T2 (https=)
PL (1) PL4284356T3 (https=)
RS (1) RS66934B1 (https=)
SM (1) SMT202500238T1 (https=)
WO (1) WO2022162199A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025093748A1 (en) * 2023-11-03 2025-05-08 3Z Pharmaceuticals Use of a calcium channel blocker in the treatment of adhd

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1030672A1 (en) * 1997-11-19 2000-08-30 Merck & Co., Inc. Method for treating attention deficit disorder
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
CA2546395A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors
EP1609783A1 (en) * 2004-06-17 2005-12-28 Neuropharma S.A.U. Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
WO2011100659A2 (en) * 2010-02-12 2011-08-18 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
PL2895507T3 (pl) * 2012-09-11 2019-04-30 Inst Catalana De Recerca I Estudis Avancats Sposób diagnostyczny do wykrywania choroby autoimmunologicznej oraz przedmioty z nim związane
WO2014133329A1 (ko) * 2013-02-27 2014-09-04 에스케이케미칼 주식회사 관절염 치료용 복합 제제
KR20140135676A (ko) * 2014-10-02 2014-11-26 한국과학기술원 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 ｔ―타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물
JP2021500416A (ja) * 2017-10-27 2021-01-07 エステベ ファーマスーティカルズ，ソシエダッド アノニマ 疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体
WO2020120606A1 (en) * 2018-12-12 2020-06-18 Esteve Pharmaceuticals, S.A. New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions

Also Published As

Publication number Publication date
CA3206935A1 (en) 2022-08-04
SMT202500238T1 (it) 2025-07-22
PL4284356T3 (pl) 2025-07-28
JP2024508372A (ja) 2024-02-27
WO2022162199A2 (en) 2022-08-04
EP4284356A2 (en) 2023-12-06
HUE071725T2 (hu) 2025-09-28
HRP20250747T1 (hr) 2025-08-15
AU2022215118A9 (en) 2024-05-16
EP4284356B1 (en) 2025-04-02
EP4284356C0 (en) 2025-04-02
RS66934B1 (sr) 2025-07-31
US20240130995A1 (en) 2024-04-25
WO2022162199A3 (en) 2022-09-15
ES3038949T3 (en) 2025-10-16

Similar Documents

Publication Publication Date Title
JP5921539B2 (ja) 下肢静止不能症候群を治療する方法
RU2757221C2 (ru) Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
EP2167066B1 (en) Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders
US20080221170A1 (en) Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
AU2011313814B2 (en) Combination therapy for the treatment of depression and other non-infectious diseases
JP2024530007A (ja) 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの使用
US20240130995A1 (en) Novel treatments
US20240002369A1 (en) Novel treatments of attention deficit/hyperactivity disorder
HK40101538A (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
HK40101538B (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
WO2025093748A1 (en) Use of a calcium channel blocker in the treatment of adhd
WO2023084054A1 (en) Treatment of adhd using selective binders of the 11-imidazoline receptor
CN117120046A (zh) 用于治疗注意力缺陷多动障碍的化合物
JP2025510790A (ja) 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの用途
CN116981460A (zh) 注意力缺陷/多动障碍的新颖治疗
US12042493B2 (en) Pharmaceutical compounds for use in treating Huntington's disease
JP2024522632A (ja) 自閉症スペクトラム障害（ａｓｄ）を治療する方法
JP6466792B2 (ja) 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
US20180042919A1 (en) PARP Inhibitors for the Treatment of Major Depressive Disorder and Related Conditions
CN118434416A (zh) 精神作用药物及其用于治疗精神和神经病状和病症的用途
CN117957003A (zh) 治疗神经退行性疾病的方法
WO2007111027A1 (ja) トリグリセリド低下剤及び高インスリン血症改善剤
HK1119078A (en) Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders

Legal Events

Date Code Title Description
SREP Specification republished